Mutacin
Systemic bacterial infections (e.g., MRSA)
Pre-clinicalActive
Key Facts
Indication
Systemic bacterial infections (e.g., MRSA)
Phase
Pre-clinical
Status
Active
Company
About Sano Chemicals
Sano Chemicals is a private, clinical-stage biotechnology company developing novel antibiotics and antifungals to address the growing crisis of antimicrobial resistance. Its lead programs include Occidiofungin for recurrent vulvovaginal candidiasis (RVVC) and other fungal infections, and Mutacin for systemic bacterial infections including MRSA. The company, which has raised $8 million, leverages new chemical entities for strong IP protection and is positioned in the high-need, high-value infectious disease market.
View full company profile